Olanzapina Nolian (Olanzapine)

Olanzapine, the active ingredient in Olanzapina Nolian, is an atypical antipsychotic presented as a strength/form for oral use. It treats schizophrenia and bipolar disorder in adults and adolescents when prescribed by a qualified health professional.

GNH USA supplies Olanzapina Nolian as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine acts on central nervous system pathways involved in psychosis and mood regulation. - Schizophrenia: reduces positive and negative symptoms and helps prevent relapse. - Bipolar I disorder (manic episodes): stabilises mood and decreases frequency of manic episodes. - Bipolar I disorder (depressive episodes): used as adjunctive therapy to improve depressive symptoms. - Schizoaffective disorder: alleviates both psychotic and mood components of the illness. - Maintenance therapy: supports long‑term symptom control after acute stabilization.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Weight gain: increased appetite leading to gradual weight increase. - Sedation: drowsiness or feeling unusually tired. - Dry mouth: reduced salivary flow causing oral discomfort. - Constipation: slowed gastrointestinal motility. - Elevated triglycerides: rise in blood lipid levels. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Hyperglycaemia/diabetes mellitus: significant rise in blood glucose. - Extrapyramidal symptoms: tremor, rigidity, bradykinesia. - Seizures: occurrence of convulsive episodes. - Agranulocytosis: marked reduction in white‑blood cell count. - Severe allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Olanzapine, clinicians should assess individual risk factors and monitor relevant clinical parameters. - Metabolic monitoring: regularly check weight, fasting glucose, and lipid profile. - Cardiovascular assessment: evaluate blood pressure and heart rate, especially in patients with pre‑existing hypotension. - Liver function: perform baseline and periodic liver enzyme tests. - Pregnancy and lactation: weigh potential benefits against risks; use only if clearly needed. - Elderly patients: start at lower doses and monitor for sedation and falls. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Olanzapine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): may increase olanzapine plasma levels and risk of toxicity. - CNS depressants (e.g., benzodiazepines, opioids): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine, rifampicin): may reduce olanzapine concentrations, diminishing therapeutic effect. - Anticholinergic agents: additive anticholinergic burden may worsen dry mouth and constipation. - Antihypertensive drugs: orthostatic hypotension may be potentiated. - Lithium: combined use may increase the risk of neurotoxicity. - Alcohol: concurrent use can intensify central nervous system depression.